Wyeth hit by drug ruling

news

Yield margins on bonds of New Jersey-based pharmaceuticals company Wyeth took a hammering in the secondary markets in May after a federal appeals court made it easier for people suing the company to present evidence suggesting they were harmed by two drugs in the company’s ‘fen-phen’ weight-loss cocktail. Hundreds of lawsuits have been filed against the company, and last month a Texas jury awarded $1.36 million to a woman who claimed her health was damaged by the slimming pills.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: